Matinas BioPharma (MTNB) Misses Q3 EPS by 1c; Reports Cash and Cash Equivalents of $53.8M
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Matinas BioPharma Reports Third Quarter 2021 Financial Results and Operational Highlights
November 8, 2021 6:35 AM ESTPositive efficacy and safety data announced from first two cohorts of patients in ongoing EnACT study of MAT2203 (oral amphotericin B) for treatment of cryptococcal meningitis; DSMB unanimously recommended progression to second half of study
Dosing initiated in Phase 1 study of potential first oral aminoglycoside antibiotic drug MAT2501 (oral amikacin)
Accomplished biotechnology executive, Kathryn Penkus Corzo, joined Companys Board of Directors
Management to host conference call today, Monday, November 8th, at 8:30 a.m. ET
BEDMINSTER, N.J., Nov. 08, 2021 (GLOBE NEWSWIRE) --... More
